TD Cowen reiterates buy on Compass Pathways stock, $29 target

TD Cowen reiterated a Buy rating on Compass Pathways with a $29 price target, citing regulatory momentum around COMP360 and the FDA's rolling NDA review. The firm now sees approval as early as Q4 2026, with a potential Q1 2027 launch, as DEA rescheduling could run in parallel with FDA review. The stock has surged 37% over the past week and is trading near its 52-week high at $9.57.

Analysis

CMPS is now trading like a binary regulatory asset rather than a traditional biotech, and that changes the holder base. The near-term bid is being driven less by clinical probability and more by the market’s willingness to capitalize a faster-than-expected review path; that can support multiple expansion, but it also makes the name vulnerable to any timeline slippage because there is still no de-risked commercial evidence in hand.

The biggest second-order effect is competitive scarcity: if this program reaches the market first, it may define payer and prescriber expectations for the entire psychedelic category. That creates an option value premium for other players in adjacent neuropsychiatric modalities, but it also raises the bar for follow-on entrants because the first mover can shape protocol, reimbursement framing, and center-of-excellence distribution before the category matures.

The risk is that the market is discounting a smooth regulatory stack when the process still has multiple gates that can move independently. Any sign the FDA and DEA workflows are less parallel than hoped would likely compress the stock sharply over days, while a clean month-by-month progression could keep momentum alive for several quarters. The asymmetry is skewed positively, but only if investors size for process risk rather than treating approval as a fait accompli.

Consensus is probably underestimating how much of the current move is sentiment-driven versus fundamental. A lot of the upside is already embedded in the stock as a probability-weighted call option on process acceleration, so the better trade may be to own convexity into upcoming regulatory milestones rather than chase common equity after a 37% run. The broader read-through is that policy can create sudden valuation resets in subscale biotech names, but only the ones with a credible path to being first in class retain the premium.

Key Decisions for Investors

• Stay long CMPS only via defined-risk structures into the next regulatory checkpoint: buy 3-6 month call spreads rather than common, because upside is still meaningful but timeline risk can reprice the stock 20-30% on a delay.
• If already long CMPS, trim 25-50% into strength and retain a core position for the Q4 2026 / Q1 2027 window; the stock is now trading ahead of execution, so the marginal dollar of upside is more expensive than a week ago.
• For higher-conviction expression on category momentum, pair a long CMPS with a short basket of lower-quality psychedelic/early-stage neuropsychiatric names that lack similar regulatory optionality; the goal is to isolate first-mover premium from the broader theme.
• Sell volatility around any short-dated spikes if implied vol decouples from realized process risk; this is a classic event-driven biotech tape where premiums can overshoot the actual probability of a catalyst.
• Set a tactical stop or hedge trigger on any evidence of the FDA/DEA process diverging; that would likely unwind the narrative quickly and is the main risk to a momentum-long trade.